Small molecule · Degrader of kinesin · developed by Boundless Bio
BBI-940 is an orally bioavailable small molecule degrader of kinesin. It degrades and inhibits kinesin, which is needed for segregating extrachromosomal DNA during mitosis, causing mis-segregation and cell cycle arrest in ecDNA-enabled cancer cells. It is being studied in breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07408089 | Phase 1 | Breast Cancer | Terminated | BOLD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Breast CancerBreast CancerMetastatic Breast Cancer
Updated Nov 8, 2026. Something wrong or missing? Report it on the BOLD page.
See BOLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BOLD catalysts and pipeline →